Skip to main content
Canna~Fangled Abstracts

Endocannabinoid System of the Blood-Brain Barrier: Current Understandings and Therapeutic Potentials

By December 16, 2021December 18th, 2021No Comments

doi: 10.1089/can.2021.0101.

Online ahead of print.
Affiliations 

Abstract

The endocannabinoid system (ECS) has been found at the blood-brain barrier (BBB), as Cannabinoid receptors were characterized in human brain microvascular endothelial cells and astrocytes. In several in vitro and in vivo studies, cannabinoids decreased BBB permeability and enhanced membrane integrity, which may be achieved through endothelial tight junctions and other mechanisms. These permeability regulation effects of cannabinoids suggested that the ECS may protect the brain by enhancing barrier integrity. Related questions about cannabinoid-drug interaction and drug distribution across the BBB are also raised. Specifically, can cannabinoids significantly reduce drug bioavailability to the brain? More in-depth and systematic investigations are needed to characterize and quantify these effects of cannabinoids on brain microvasculature physiopathology. Therefore, this review summarizes literatures from different disciplines to promote more research on assessing the therapeutic benefits and risks of using cannabinoids to protect BBB from dysfunctions or breakdown, and to avoid consequent brain damages due to inflammation, neurodegenerations, hemorrhage, ischemia, or other causes.

 

Keywords: blood–brain barrier, drug interaction, human brain microvascular cells, ischemia, permeability, stroke


Leave a Reply